These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33184267)

  • 21. Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy.
    Lázár-Molnár E; Scandiuzzi L; Basu I; Quinn T; Sylvestre E; Palmieri E; Ramagopal UA; Nathenson SG; Guha C; Almo SC
    EBioMedicine; 2017 Mar; 17():30-44. PubMed ID: 28233730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.
    Speranza MC; Passaro C; Ricklefs F; Kasai K; Klein SR; Nakashima H; Kaufmann JK; Ahmed AK; Nowicki MO; Obi P; Bronisz A; Aguilar-Cordova E; Aguilar LK; Guzik BW; Breakefield X; Weissleder R; Freeman GJ; Reardon DA; Wen PY; Chiocca EA; Lawler SE
    Neuro Oncol; 2018 Jan; 20(2):225-235. PubMed ID: 29016938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mitochondrial Pyruvate Import Promotes Long-Term Survival of Antibody-Secreting Plasma Cells.
    Lam WY; Becker AM; Kennerly KM; Wong R; Curtis JD; Llufrio EM; McCommis KS; Fahrmann J; Pizzato HA; Nunley RM; Lee J; Wolfgang MJ; Patti GJ; Finck BN; Pearce EL; Bhattacharya D
    Immunity; 2016 Jul; 45(1):60-73. PubMed ID: 27396958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intratumoral Tcf1
    Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
    Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Lived Plasma Cells in Mice and Men.
    Brynjolfsson SF; Persson Berg L; Olsen Ekerhult T; Rimkute I; Wick MJ; Mårtensson IL; Grimsholm O
    Front Immunol; 2018; 9():2673. PubMed ID: 30505309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.
    Pascual M; Mena-Varas M; Robles EF; Garcia-Barchino MJ; Panizo C; Hervas-Stubbs S; Alignani D; Sagardoy A; Martinez-Ferrandis JI; Bunting KL; Meier S; Sagaert X; Bagnara D; Guruceaga E; Blanco O; Celay J; Martínez-Baztan A; Casares N; Lasarte JJ; MacCarthy T; Melnick A; Martinez-Climent JA; Roa S
    Blood; 2019 May; 133(22):2401-2412. PubMed ID: 30975638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
    Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
    Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
    Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.
    Azpilikueta A; Agorreta J; Labiano S; Pérez-Gracia JL; Sánchez-Paulete AR; Aznar MA; Ajona D; Gil-Bazo I; Larrayoz M; Teijeira A; Rodriguez-Ruiz ME; Pio R; Montuenga LM; Melero I
    J Thorac Oncol; 2016 Apr; 11(4):524-36. PubMed ID: 26845193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 31. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
    Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-affinity human programmed death-1 ligand-1 variant promotes redirected T cells to kill tumor cells.
    Liang Z; Li Y; Tian Y; Zhang H; Cai W; Chen A; Chen L; Bao Y; Xiang B; Kan H; Li Y
    Cancer Lett; 2019 Apr; 447():164-173. PubMed ID: 30677447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteasome Inhibition with Bortezomib Induces Apoptosis of Long-Lived Plasma Cells in Steroid-Resistant or Relapsed Immune Thrombocytopaenia.
    Li G; Wang S; Li N; Liu Y; Feng Q; Zuo X; Li X; Hou Y; Shao L; Ma C; Gao C; Hou M; Peng J
    Thromb Haemost; 2018 Oct; 118(10):1752-1764. PubMed ID: 30235480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy.
    Zhang C; Peng Y; Hublitz P; Zhang H; Dong T
    Sci Rep; 2018 Apr; 8(1):5549. PubMed ID: 29615718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
    Zolov SN; Rietberg SP; Bonifant CL
    Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma.
    Wei M; Liu X; Cao C; Yang J; Lv Y; Huang J; Wang Y; Qin Y
    BMB Rep; 2018 Nov; 51(11):572-577. PubMed ID: 30021673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.
    Schlenker R; Olguín-Contreras LF; Leisegang M; Schnappinger J; Disovic A; Rühland S; Nelson PJ; Leonhardt H; Harz H; Wilde S; Schendel DJ; Uckert W; Willimsky G; Noessner E
    Cancer Res; 2017 Jul; 77(13):3577-3590. PubMed ID: 28533272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differentiation and maintenance of long-lived plasma cells.
    Kometani K; Kurosaki T
    Curr Opin Immunol; 2015 Apr; 33():64-9. PubMed ID: 25677584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors.
    Taddeo A; Khodadadi L; Voigt C; Mumtaz IM; Cheng Q; Moser K; Alexander T; Manz RA; Radbruch A; Hiepe F; Hoyer BF
    Arthritis Res Ther; 2015 Mar; 17(1):39. PubMed ID: 25889236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
    Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.